Clinical Trial Update: Study of Two Dose Levels of RTA 402 in Patients With Advanced Malignant Melanoma [Phase 2]

View source ↗

Summary

This entry reports the withdrawal of a Phase 2 study evaluating two dose levels of RTA 402 in patients with advanced malignant melanoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• RTA 402 (bardoxolone methyl)

Snippet

Sponsor: Biogen | Conditions: Malignant Melanoma | Phase 2 | Status: WITHDRAWN